IL1B and atherosclerosis: The authors argue that this study [141] fulfills Koch's postulates for ASCVD since inflammation, including the proinflammatory cytokine, IL-1β, has been shown in animal models to contribute to atherosclerosis, and now, this study shows that blocking IL-1 with the 150 mg dose in humans results in a significant decrease in cardiovascular events [170].